Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis

por Freedman, Mark S
Publicado 2014

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study

por Freedman, Mark S, Morawski, Julia, Thangavelu, Karthinathan
Publicado 2018

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021

por Freedman, Mark S., Ault, Kevin, Bernstein, Henry
Publicado 2021

Blood Neurofilament Light Chain: The Neurologist’s Troponin?

por Thebault, Simon, Booth, Ronald A., Freedman, Mark S.
Publicado 2020

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2020

por Freedman, Mark S., Hunter, Paul, Ault, Kevin, Kroger, Andrew
Publicado 2020

Tolerability and discontinuation rates in teriflunomide-treated patients: A real-world clinical experience

por Alnajashi, Hind A., Alshamrani, Foziah J., Freedman, Mark S.
Publicado 2018

Serum neurofilament light in MS: The first true blood-based biomarker?

por Thebault, Simon, Bose, Gauruv, Booth, Ronald, Freedman, Mark S
Publicado 2021

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis

por Freedman, Mark S., Jack, Dominic, Murgašová, Zuzana, Todorović, Milorad, Seitzinger, Andrea
Publicado 2021

CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent

por Thebault, Simon, Bergman, Hailey, Atkins, Harold L., Freedman, Mark S., Brooks, John
Publicado 2022

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo

por Vermersch, Patrick, Radue, Ernst-Wilhelm, Putzki, Norman, Ritter, Shannon, Merschhemke, Martin, Freedman, Mark S
Publicado 2017

Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

por Thebault, Simon, Booth, Ronald A., Rush, Carolina A., MacLean, Heather, Freedman, Mark S.
Publicado 2021

Human oligodendrocytes are susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes()

por Ruijs, Theodora C.G., Freedman, Mark S., Grenier, Yannick G., Olivier, André, Antel, Jack P.
Publicado 1990

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

por Thebault, Simon, Abdoli, Mohammad, Fereshtehnejad, Seyed-Mohammad, Tessier, Daniel, Tabard-Cossa, Vincent, Freedman, Mark S.
Publicado 2020

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials

por Comi, Giancarlo, Miller, Aaron E, Benamor, Myriam, Truffinet, Philippe, Poole, Elizabeth M, Freedman, Mark S
Publicado 2019

gMS-Classifier1 does not predict disability progression in multiple sclerosis

por van Rossum, Johannis A, Killestein, Joep, Villar, Luisa M, Riskind, Peter N, Freedman, Mark S, Teunissen, Charlotte
Publicado 2018

Routine HIV Testing among Providers of HIV Care in the United States, 2009

por McNaghten, A. D., Valverde, Eduardo E., Blair, Janet M., Johnson, Christopher H., Freedman, Mark S., Sullivan, Patrick S.
Publicado 2013

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

por Freedman, Mark S., Brod, Staley, Singer, Barry A., Cohen, Bruce A., Hayward, Brooke, Dangond, Fernando, Coyle, Patricia K.
Publicado 2019

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression

por Law, Marco TK, Traboulsee, Anthony L, Li, David KB, Carruthers, Robert L, Freedman, Mark S, Kolind, Shanon H, Tam, Roger
Publicado 2019

Physical Activity Together for People With Multiple Sclerosis and Their Care Partners: Protocol for a Feasibility Randomized Controlled Trial of a Dyadic Intervention

por Fakolade, Afolasade, Cameron, Julie, McKenna, Odessa, Finlayson, Marcia L, Freedman, Mark S, Latimer-Cheung, Amy E, Pilutti, Lara A
Publicado 2021

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS

por Ackermans, Nathalie, Taylor, Carolyn, Tam, Roger, Carruthers, Robert, Kolind, Shannon, Kang, Heejun, Freedman, Mark S, Li, David KB, Traboulsee, Anthony L
Publicado 2019